| abstract |
The present disclosure provides a method for the treatment of cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a first agent and a therapeutically effective amount of one or more second agents, respectively. It relates to the compounds used and the medicaments. Preferably, the first agent comprises an EZH2 inhibitor. In certain embodiments, the first agent is tazemetstat or a pharmaceutically acceptable salt thereof, and the methods of the present disclosure are used to treat multiple myeloma or mantle cell lymphoma. |